OHSU in the news

Spero Therapeutics announces first patient dosed with SPR720 in Phase 2a clinical trial in patients with nontuberculous mycobacterial pulmonary disease

Spero Therapeutics December 10, 2020
Kevin Winthrop, M.D., M.P.H., is featured in a Spero Therapeutics press release announcing the inaugural dosing of patients with nontuberculous mycobacterial pulmonary disease with an antimicrobial agent as a part of a Phase 2a clinical trial. Winthrop says: “Oral SPR720 shows potential to benefit patients with NTM pulmonary disease and we are excited to have initiated this novel Phase 2a trial to assess SPR720 in patients with early onset pulmonary disease.”

9 things to know about adjuvant therapy for melanoma

Health Central December 10, 2020
In a Health Central slideshow on recurrence of melanoma following surgery, Sancy Leachman, M.D., Ph.D., says “If you’ve got a little bit of spread, we know your risk of spread elsewhere is high.”

10 scientific discoveries in 2020

Laboratory Equipment December 10, 2020
OHSU’s work to provide the first CRISPR gene editing procedure within the human body to treat an inherited cause of blindness was named the No. 3 top scientific discovery of 2020.

Although childhood cancer survival rates have improved, survivors face disability-related challenges throughout adulthood

National Academies of Sciences, Engineering, Medicine December 09, 2020
Brandon Hayes-Lattin, M.D., participates in Committee on Childhood Cancers and Disability, co-authors report that finds Survivors of childhood cancer have an increased risk of experiencing disabling conditions, both from the cancer itself and from the effects of treatment. He says: “Recognizing that systems for both clinical care and for disability determinations change at the intersection of adolescence and young adulthood, the report’s findings on this transition for AYA cancer survivors is particularly meaningful.”

Study: Damage to brain cells Reverberates to 'bystander' cells

Laboratory Equipment December 09, 2020
News coverage of new research by Marc Freeman, Ph.D., and colleagues revealing that injury or disease that afflicts a relatively small number of brain cells causes a chain reaction that stops activity across a vast network of neural circuits.
See more stories